Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mike Kratky has given his Hold rating due to a combination of factors related to Inspire Medical Systems’ recent developments. The announcement of CFO Rick Buchholz’s departure, effective at the end of the year, introduces a level of uncertainty as the company searches for a new financial leader. Despite this leadership change, the company has maintained its financial guidance for FY25, projecting sales between $900-910 million, a gross margin of 84-86%, and diluted EPS of $0.40-0.50.
While the reaffirmation of the FY25 guidance could be seen as a stabilizing factor, it does not present any significant surprises, especially given that a substantial portion of the third quarter has already been completed. The combination of a stable financial outlook amidst leadership changes suggests a cautious approach, warranting a Hold rating as investors might want to wait for further clarity on the company’s strategic direction and leadership transition.
INSP’s price has also changed dramatically for the past six months – from $196.610 to $91.750, which is a -53.33% drop .